Allogeneic transplantation in Cutaneous T-cell Lymphoma: improved outcomes associated with early transplantation and acute graft versus host disease

Angelov, Daniel; Dillon, James; Mellerick, Lisa; Pender, Emily S.; Bacon, Larry; Lee, Greg; Higgins, Liz; McCarty, Heather; Gillham, C.; Quinn, John; O’Gorman, Susan; Leonard, Niamh; McMenamin, Máirín; Vandenberghe, Elisabeth

doi:10.1038/s41409-022-01713-7

Cited by 3 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data on the role of allo-HSCT in CTCL are also limited, and no prospective trials have been performed to date. Retrospective registry analyses on allo-HSCT in CTCL include the 2010 and 2021 European Society for Blood and Marrow Transplantation (EBMT) studies, the 2014 CIBMTR study, and the 2020 Japanese Society for Hematopoietic Cell Transplantation study [ 19 – 23 ]. These retrospective registry studies of CTCL report rates of acute GVHD at 35% to 87% and chronic GVHD at 32% to 48% [ 19 – 23 ].…”

Section: Discussionmentioning

confidence: 99%

Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis

Lechowicz,

Smith,

Ristuccia

et al. 2024

Int J Hematol

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important therapy for patients with T-cell lymphomas, including cutaneous T-cell lymphoma (CTCL), adult T-cell lymphoma (ATL), and peripheral T-cell lymphoma (PTCL). Mogamulizumab is an anti-CCR4 antibody that has been associated with an increased risk of transplant-related complications in retrospective analyses of ATL, particularly when administered within 50 days before transplantation. This post hoc analysis of 3 clinical trials examined safety and outcome data for 32 patients with CTCL (n = 23), ATL (n = 7), or PTCL (n = 2) who underwent allo-HSCT after mogamulizumab treatment. Overall, 22 patients (69%) were known to have graft-versus-host disease (GVHD), 8 patients (25%) did not report GVHD, and 2 patients (6%) had unknown GVHD status. Fourteen patients with known GVHD underwent transplantation between 50 and 365 days after their last dose of mogamulizumab, while 2 underwent transplantation within 50 days after treatment. Based on this limited evidence, GVHD was not associated with the time interval from last mogamulizumab dose to transplantation.

show abstract